



HOUSE BILL 35: Expand Definition of Opioid Antagonist.

2023-2024 General Assembly

Committee:	House Rules, Calendar, and Operations of the House	Date:	February 21, 2023
Introduced by:	Reps. Sasser, Potts, Lambeth, Paré	Prepared by:	Jessica Boney
Analysis of:	First Edition		Staff Attorney

OVERVIEW: *House Bill 35 would broaden the definition of opioid antagonist to mean all opioid antagonists approved by the federal Food and Drug Administration ("FDA") to treat drug overdoses, instead of only naloxone hydrochloride, and would allow State Needle and Hypodermic Syringe Exchange Programs to use FDA approved opioid antagonists.*

BILL ANALYSIS: Section 1 would amend the definition of opioid antagonist found in G.S. 90-12.7 (Treatment of overdose with opioid antagonist; immunity) to include all opioid antagonists approved by the FDA, instead of only naloxone hydrochloride.

Section 2 would make conforming changes to G.S. 90-113.27 (Authorization of needle and hypodermic syringe exchange programs) by replacing "naloxone hydrochloride" with "opioid antagonist" and replacing "naloxone kits" with "opioid antagonist kits". The conforming changes would allow Needle and Hypodermic Syringe Exchange Programs to use all FDA approved opioid antagonists.

EFFECTIVE DATE: This act would be effective when it became law.

Jeffrey Hudson
Director



Legislative Analysis
Division
919-733-2578